Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 3.

Schrappe, M; Valsecchi, M G; Bartram, C R; Schrauder, A; Panzer-Grümayer, R; Möricke, A; Parasole, R; Zimmermann, M; Dworzak, M; Buldini, B; Reiter, A; Basso, G; Klingebiel, T; Messina, C; Ratei, R; Cazzaniga, G; Koehler, R; Locatelli, F; Schäfer, B W; Aricò, M; Welte, K; van Dongen, J J M; Gadner, H; Biondi, A; Conter, V (2011). Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood, 118(8):2077-2084.

Möricke, A; Zimmermann, M; Reiter, A; Henze, G; Schrauder, A; Gadner, H; Ludwig, W D; Ritter, J; Harbott, J; Mann, G; Klingebiel, T; Zintl, F; Niemeyer, C; Kremens, B; Niggli, F; Niethammer, D; Welte, K; Stanulla, M; Odenwald, E; Riehm, H; Schrappe, M (2010). Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia, 24(2):265-284.

Möricke, A; Reiter, A; Zimmermann, M; Gadner, H; Stanulla, M; Dördelmann, N; Löning, L; Beier, R; Ludwig, W D; Ratei, R; Harbott, J; Boos, H; Mann, G; Niggli, F; Feldges, A; Henze, G; Welte, K; Beck, J D; Klingebiel, T; Niemeyer, C; Zintl, F; Bode, U; Urban, C; Wehinger, H; Niethammer, D; Riehm, H; Schrappe, M (2008). Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood, 111(9):4477-4489.

This list was generated on Sun Feb 24 06:07:50 2019 CET.